Department of Cardiology, Hillel Yaffe Medical Center, Hadera, Israel.
Department of Clinical Biochemistry, Hadassah University Hospital, Jerusalem, Israel.
J Int Med Res. 2022 Oct;50(10):3000605221127099. doi: 10.1177/03000605221127099.
Inflammation is associated with atherogenesis. Although a higher neutrophil count is associated with the plaque burden, the role of neutrophil activation is unclear. Human neutrophil peptides 1-3 (HNP1-3) are a risk factor for atherogenesis in bench models and are elevated in human atheromas. This study aimed to examine the association between skin HNP1-3 deposition and the severity of coronary artery disease (CAD), including long-term outcomes.
HNP1-3 levels were immunohistochemically quantified in skin biopsies, which were prospectively taken from 599 consecutive patients before clinically indicated coronary angiography. Established cardiovascular risk factors and blood markers for atheroinflammation were obtained. CAD severity and the incidence of repeat revascularization and mortality at 48 months of follow-up were assessed in relation to HNP1-3 levels.
The risk of CAD was independently associated with age and HNP1-3 in the entire cohort (F = 0.71 and F = 7.4, respectively). Additionally, HNP1-3 levels were significantly associated with myocardial necrosis (R = 0.26). At the follow-up, high HNP1-3 levels negatively affected mortality (19.54%) and recurrent revascularization (8.05%).
HNP1-3 tissue deposition is positively associated with the severity of CAD, myonecrosis, and long-term sequelae. HNP1-3 levels may be suppressed using colchicine.
炎症与动脉粥样硬化形成有关。虽然中性粒细胞计数较高与斑块负担相关,但中性粒细胞激活的作用尚不清楚。人中性粒细胞肽 1-3(HNP1-3)是体外模型中动脉粥样硬化形成的危险因素,且在人类动脉粥样瘤中升高。本研究旨在探讨皮肤 HNP1-3 沉积与冠状动脉疾病(CAD)严重程度的关系,包括长期预后。
在 599 例连续患者进行临床指征冠状动脉造影之前,前瞻性地对其皮肤活检进行 HNP1-3 免疫组化定量。获得了已建立的心血管危险因素和动脉粥样炎症的血液标志物。根据 HNP1-3 水平评估 CAD 严重程度以及 48 个月随访时重复血运重建和死亡率的发生率。
在整个队列中,CAD 的风险与年龄和 HNP1-3 独立相关(F=0.71 和 F=7.4)。此外,HNP1-3 水平与心肌坏死显著相关(R=0.26)。在随访期间,高 HNP1-3 水平对死亡率(19.54%)和再血运重建(8.05%)有负面影响。
HNP1-3 组织沉积与 CAD、心肌坏死和长期后果的严重程度呈正相关。可以使用秋水仙碱抑制 HNP1-3 水平。